Cytotoxic chemotherapy in the contemporary management of metastatic castration‐resistant prostate cancer (mCRPC)
Sonpavde G, Wang C, Galsky M, Oh W, Armstrong A. Cytotoxic chemotherapy in the contemporary management of metastatic castration‐resistant prostate cancer (mCRPC). BJU International 2014, 116: 17-29. PMID: 25046451, DOI: 10.1111/bju.12867.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate cancerManagement of metastatic castration-resistant prostate cancerTreatment of metastatic castration-resistant prostate cancerMetastatic castration-sensitive prostate cancerCastration-sensitive prostate cancerDevelopment of multiple agentsImproved survival of patientsResistance to available agentsOptimal sequence of treatmentOptimise treatment benefitTiming of chemotherapySurvival of patientsSelection of patientsManagement of patientsDeclining performance statusLong-term outcomesCytotoxic chemotherapySequence of treatmentPerformance statusPredictive biomarkersImproved survivalPatient selectionChemotherapeutic agents
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply